ADAP Crosses Above Average Analyst Target
March 16, 2018 at 09:29 AM EDT
In recent trading, shares of Adaptimmune Therapeutics PLC (ADAP) have crossed above the average analyst 12-month target price of $10.20, changing hands for $10.94/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..